Stripe, Anthropic, and OpenAI are backing an effort to stop respiratory infections

· Source: MIT Technology Review · Field: Health & Wellbeing — Public Health & Epidemiology, Pharmaceuticals & Biotechnology, Artificial Intelligence & Machine Learning · Depth: Fundamental Awareness, short

Summary

A new nonprofit, Intercept, backed by Stripe, Anthropic, OpenAI Foundation, Flu Lab, Bill Gates, and Jane Street Capital traders, has launched with \$500 million to prevent common colds and the flu, ultimately aiming to eradicate all respiratory viruses. Led by Stripe executive Nan Ransohoff and venture capitalist Charlie Petty, Intercept will fund prevention approaches, including broad-spectrum vaccines and large-scale air-cleaning systems for public spaces. This initiative addresses the significant societal burden of respiratory infections, which cause individuals to spend 5% of their lifetime fighting illness, despite pharmaceutical companies' limited investment due to the over 200 causative viruses and insufficient commercial incentives. The project draws inspiration from Stripe's \$1.8 billion Frontier carbon removal program and COVID-19 vaccine development efforts, seeking to overcome similar "incentive problems" by applying modern technologies like RNA drugs and computational protein design. Advisors include former FDA official Peter Marks and Operation Warp Speed lead Moncef Slaoui.

Key takeaway

For research scientists and public health strategists evaluating underfunded health challenges, this initiative highlights a model for addressing problems where commercial incentives are weak. You should consider how private philanthropic capital, exemplified by Intercept's \$500 million commitment, can accelerate development of broad-spectrum countermeasures and air purification technologies against pervasive threats like respiratory viruses. Explore opportunities for collaboration or funding from similar initiatives to apply modern biotechnologies to neglected areas.

Key insights

Private philanthropy can drive solutions for technically possible problems lacking commercial incentives, like preventing respiratory viruses.

Principles

Method

Intercept will use grants and investments to back broad prevention approaches, including vaccines and large-scale air-cleaning systems, overcoming commercial disincentives.

In practice

Topics

Best for: Investor, Tech Journalist, Research Scientist, Executive

Related on AIssential

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by MIT Technology Review.